



03/31/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of

PAGE

Atty. Ref: 1430-95

U.S. Patent No. 5,545,404

Issued: August 13, 1996

For: **METHOD FOR TREATING A MAMMAL
SUFFERING FROM A T-CELL MEDIATED
DISORDER WITH A CHO-GLYCOSYLATED
ANTIBODY**

* * * * *

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

PETITION UNDER 37 CFR 1.324

Sir:

The undersigned respectfully request that the above-identified patent be corrected to name as actual inventors the following individuals:

Martin John Page

James Scott Crowe

For the reasons set forth in the attached verified statement, James Scott Crowe was not named in the application from which this patent derives as originally filed through error without any deceptive intention on the part of any of the actual inventors.



03/31/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of

PAGE

Atty. Ref: 1430-95

U.S. Patent No. 5,545,404

Issued: August 13, 1996

For: **METHOD FOR TREATING A MAMMAL
SUFFERING FROM A T-CELL MEDIATED
DISORDER WITH A CHO-GLYCOSYLATED
ANTIBODY**

* * * * *

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

CERTIFICATION UNDER 37 CFR 3.73(b)

Sir:

The assignment for the application from which this patent derives to Burroughs Wellcome Co. was recorded on May 13, 1992, on Reel/Frame 6109/0549 (assignment from inventor to Wellcome Foundation Limited) and Reel/Frame 6109/0554 (assignment from Wellcome Foundation Limited to Burroughs Wellcome Co.). Attached is a copy of a North Carolina Certificate showing the name of Burroughs Wellcome Co. was changed to Glaxo Wellcome Inc. effective as of October 31, 1995 (together with a Recordation Form Cover Sheet dated October 3, 1996). Assignee has reviewed the evidentiary documents for the aforesaid chain of title and hereby certifies that, to the best of assignee's knowledge and belief, title is in Glaxo Wellcome Inc. by virtue of the above-noted assignment and name change. I am empowered to act on behalf of Glaxo Wellcome Inc.

Grant of this Petition and acknowledgment of the correction of inventorship are requested.

Respectfully submitted,

29.1.97

Date

Mck John Page

Martin John Page

29th January 1997

Date

James Scott Crowe

James Scott Crowe

11th FEBRUARY 1997

Date

David J. Levy

Name: DAVID J. LEVY

Title: ASSISTANT SECRETARY

Glaxo Wellcome Inc.

MJW:tat

1100 North Glebe Road, 8th Floor

Arlington, Virginia 22201-4714


Tel.: (703) 816-4000/Fax: (703) 816-4100

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

GLAXO WELLCOME INC.

Date: FEBRUARY 11, 1997
Glaxo Wellcome Inc.
Five Moore Drive
Research Triangle Park, NC 27709
Telephone No.: (919) 483-2723
Facsimile No.: (919) 483-7988


By: David J. Levy
Title: Assistant Secretary and
Patent Counsel
Registration No.: 27,655